pramipexole

(redirected from Sifrol)
Also found in: Medical.
Related to Sifrol: pramipexole, Madopar

pram·i·pex·ole

 (prăm′ə-pĕk′sōl′)
n.
A dopamine agonist used in the treatment of Parkinson's disease.

[pr(opyl) + ami(no) + pex-, of unknown meaning + (thiaz)ole.]
Translations

pramipexole

n pramipexol m
References in periodicals archive ?
000 dolares de los laboratorios Boehringer Ingelheim [R], que comercializa Sifrol [R] (pramipexol).
The market is dominated by branded products such as Boehringer Ingelheim's Mirapex/Mirapexin / Sifrol / Mirapex ER / Mirapexin ER (pramipexole), GlaxoSmithKline's (GSK) Requip/Requip XL (ropinirole), Orion / Novartis' Stalevo/Comtan (carbidopa/levodopa/entacapone) and Teva/Lundbeck's Azilect/Agilect (rasagiline).
The findings also reveal that although interviewed experts have similar views of immediate-release and extended-release pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol, generics; Mirapex ER/Mirapexin ER, Sifrol Retard) and immediate-release and controlled-release ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab/Prolib), a higher percentage of surveyedneurologists chose pramipexole (26 percent) over ropinirole (18 percent) as the most effective agent for the treatment of advanced Parkinson's disease.